Frank Thompson
For two years, the Medicare drug price negotiation program has run on administrative guidance, which is essentially rules that the next administration could rewrite or ignore. On June 12, 2026, CMS changed that. The agency published proposed rule CMS-4215-P, which would lock the negotiation program into permanent federal regulation for the first time. If you’re on Medicare Part D, or about to be, this matters more than most policy news you’ll scroll past this week.
What the Proposed Rule Actually Does
The short version: CMS wants to move the negotiation program from “we’re doing this via guidance” to “this is codified federal regulation.” That shift is significant because guidance can be reversed with a memo. A finalized rule requires a formal rulemaking process to undo, which creates a much higher bar for any future rollback.
The rule governs negotiations beginning with the Initial Price Applicability Year 2029. The cycles covering 2026, 2027, and 2028 drug negotiations stay under existing guidance and aren’t affected. So this is forward-looking, building the permanent architecture for where the program goes next, not renegotiating what’s already done.
Starting with the 2029 cycle, CMS will be able to select up to 20 drugs per year for negotiation, covering both Medicare Part D (outpatient prescriptions) and Medicare Part B (drugs administered in a doctor’s office or clinic, like infusions). That’s an expansion worth noting. Part B drugs have historically been priced through a different mechanism, and pulling them more fully into the negotiation framework is a meaningful structural change.
CMS expects to finalize the rule this fall, according to the agency’s press release. The public comment window closes August 17, 2026.
The Numbers Already on the Board
| Program Cycle | Number of Drugs Negotiated | Key Detail | Effective Date |
|---|---|---|---|
| Cycle 1 (Original batch) | 10 | Initial IRA drugs | January 1, 2026 |
| Cycle 2 | 15 | 44% average net savings; Ozempic/Wegovy 71% reduction | January 1, 2027 |
| Cycle 3+ (2029 onward) | Up to 20 per year | Includes Part B drugs; permanent regulation | Proposed framework |
| Total negotiated (through Cycle 2) | 25 | Covers Part D and Part B (2029+) | - |
Helpful resource: Medicare and You 2024 Official Handbook (Amazon) is a top-rated option for this. (As an Amazon Associate this site earns from qualifying purchases.)
Before getting too abstract about regulatory frameworks, it helps to look at what the program has already produced.
CMS has negotiated prices for 25 high-expenditure drugs across the program’s first two cycles. The first 10 of those, the original batch selected under the Inflation Reduction Act, hit their negotiated maximum fair prices on January 1, 2026. The second cycle delivered a 44% average net savings across 15 drugs. The headline figure from that second round is the 71% list-price reduction for Ozempic and Wegovy (semaglutide), effective January 1, 2027. Those are two of the most prescribed and most expensive drugs in the country right now, so that reduction is not a rounding error.
For context on what this means in practice: if you’re currently paying a percentage-based coinsurance for one of these negotiated drugs, your out-of-pocket costs track the list price. A 71% price reduction doesn’t necessarily mean you pay 71% less at the counter, because your actual cost depends on your plan design, deductible, and what phase of the Part D benefit you’re in. But lower list prices do reduce what both you and Medicare pay, and the $2,000 annual out-of-pocket cap that took effect in 2025 under the IRA (Inflation Reduction Act) provides a ceiling regardless.
Why “Permanent” Is the Operative Word
The legal analysis from Holland & Knight notes that the shift from guidance to rulemaking creates a more durable and enforceable structure. Guidance documents are internal policy. A finalized federal regulation, by contrast, carries the force of law and can only be changed through the full notice-and-comment rulemaking process, the same process CMS is running right now.
This distinction matters because the negotiation program has faced ongoing legal challenges from pharmaceutical manufacturers since its inception. Codifying the program in regulation doesn’t make it litigation-proof, but it does make administrative reversal significantly harder. For someone who depends on a negotiated-price drug, “harder to reverse” is better than “easy to undo.”
The Duane Morris LLP alert on the proposed rule points out that the 2029 cycle framework also sets clearer procedural rules for how CMS conducts negotiations, which drugs qualify, and how manufacturers can engage in the process. More defined procedures tend to produce more predictable outcomes, and predictability benefits patients planning their drug coverage.
What This Means If You’re on Medicare Now
If you’re currently taking one of the 25 drugs already negotiated, the proposed rule doesn’t change your 2026 prices. Those are set. What it does is tell you the program that produced those prices isn’t going anywhere if CMS gets this finalized on its expected timeline.
If you’re choosing a Part D plan during Open Enrollment this fall (which runs October 15 through December 7), the negotiated prices for the second-cycle drugs take effect January 1, 2027. That means plan formularies and premium structures for 2027 should, in theory, reflect those lower prices. Watch for that when comparing plans on Medicare.gov’s Plan Finder tool.
If you’re not yet on Medicare but will be in the next few years, the 2029 cycle is the one to watch. Up to 20 drugs per year negotiated under a permanent regulatory framework is a substantially larger program than where this started. Drugs that aren’t negotiated yet may be by the time you enroll.
How to Make Your Voice Count Before August 17
The 60-day public comment period on CMS-4215-P closes August 17, 2026. This is a formal federal rulemaking process, which means CMS is legally required to read and respond to substantive comments. Your experience as a patient, caregiver, or Medicare beneficiary counts as substantive.
You can submit comments directly through the Federal Register at federalregister.gov/documents/2026/06/16/2026-12059. Plain language is fine. You don’t need a law degree. What you do need is specificity: if a negotiated drug has changed what you pay or what you can afford, say that. Concrete patient experience carries weight in these proceedings.
The program is also not without critics. Pharmaceutical companies argue that negotiated prices reduce revenue available for drug development. That debate is real and ongoing, and it’s worth reading perspectives from multiple sources before commenting. SHIP (State Health Insurance Assistance Program) counselors in your state can help you understand how current and proposed changes might affect your specific plan.
CMS has built something real here over two years. Whether the proposed permanent framework survives legal challenges, political shifts, and the comment process intact, nobody can say for certain. What’s clear right now is that the comment window is open, the stakes are concrete, and August 17 comes fast.
Sources
- CMS Proposed Rule Locks in Lower Prices and Fosters Innovation for the Medicare Drug Price Negotiation Program (June 12, 2026)
- Federal Register: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (CMS-4215-P) (June 16, 2026)
- CMS Issues First Proposed Rule for IRA Medicare Drug Price Negotiation , Holland & Knight (June 2026)
- CMS Proposes Permanent Framework for Medicare Drug Price Negotiation Program , Duane Morris LLP (June 2026)
- CMS proposes permanent framework for Medicare drug price negotiations , Fierce Healthcare (June 2026)
This article is for informational purposes only. Medicare rules change annually. Always verify current plan details at Medicare.gov or by calling 1-800-MEDICARE (1-800-633-4227). This site does not sell insurance or recommend specific plans.
Recommended Resources
Disclosure: As an Amazon Associate, we earn a small commission from qualifying purchases at no extra cost to you. We only recommend products that genuinely support the topics covered in this article.
- Medicare For Dummies (~$22), The definitive consumer guide to Medicare, enrollment windows, Part A/B/C/D, and supplement plans.
- Get What’s Yours for Medicare (~$17), Maximize your Medicare benefits and minimize out-of-pocket costs. Covers Part D drug coverage gaps and Medigap in depth.
